



P : +61 8 6465 5500

🐦 : EveInvestments

🌐 : Eve Investments Limited

W : [www.eveinvestments.com.au](http://www.eveinvestments.com.au)

11 October 2021

## Omni Innovation: New Partner Launches Product

### Highlights

- **Pre-meal drink launch underway under new licence agreement between Omni Innovation (38% EVE) and Myopharm Limited**
- **Diabetes pre-meal drink launched as Omni-D™**
- **On-going royalties to commence with product sales**
- **Licensing opportunities being pursued in international territories**

**EVE Investments (ASX:EVE, EVE or the Company)**, a vertically integrated health, nutrition and wellness company, provides an update on activities at Omni Innovation, owned 38% by EVE.

### Omni Innovation

#### **Licensing Agreement**

The Company previously advised that Omni Innovation (38% owned by EVE) had entered into a binding Term Sheet agreement with Myopharm Limited (“Myopharm”), an unlisted Australian biotechnology company, for a 15-year licence for the manufacture, marketing and distribution of Omni Innovation’s foundation product, the clinically proven pre-meal glycaemic control product for Type 2 diabetes and Pre-Type 2 diabetes (See ASX Release 14 January 2021).

In Australia, there are approximately one million people living with Type 2 diabetes, with a further two million people with pre-diabetes.<sup>1</sup> Omni Innovation’s pre-meal glycaemic product reduces the blood glucose spike that occurs after consuming a standard meal and in the long term improve overall glycaemic control (HbA1c levels), this provides a drug-free alternative to those seeking to manage their Type-2 diabetes or pre-diabetes. Globally, Type 2 diabetes and pre-diabetes are amongst the fastest growing chronic medical conditions.

Since entering into the agreement earlier this year, Myopharm, supported by Omni Innovation, have been continuing to progress activities towards a consumer launch of Omni Innovation’s product with activities including brand development, packaging development and work to establish consumer pathways.

Under brand name, Omni-D™ the product was recently launched to participants at the Australasian Diabetes Congress, this step is in the leadup to a full consumer launch early in 2022 through healthcare and allied health network in Australia.

---

<sup>1</sup> <https://www.aihw.gov.au/reports/diabetes/diabetes/contents/how-many-australians-have-diabetes/type-2-diabetes> & <https://www.diabetesaustralia.com.au/about-diabetes/pre-diabetes/>



P : +61 8 6465 5500

🐦 : EveInvestments

🌐 : Eve Investments Limited

W : [www.eveinvestments.com.au](http://www.eveinvestments.com.au)

Omni Innovation has also licensed the product to Myopharm for China, Europe and the UK and these launches are also expected to follow later in 2022.

Omni Innovation has already received \$0.5m in upfront consideration, with a further \$0.4m to arrive in stages through to FY24. On-going royalties to Omni Innovation, with significant minimum annual payments to maintain exclusivity, are also payable under the agreement between the parties based off product sales in the territories.



Image 1: Recently revised packaging under the Omni-D™ brand name.

### ***International Opportunities***

Omni Innovation continues to pursue licensing arrangements in other territories including the USA and India, both territories with large populations of those living with diabetes and pre-diabetes as well as being markets that Omni has patented its pre-meal drink technology. Omni Innovation expects to leverage of a successful relaunch of the product by Myopharm in Australia, and the other territories it holds, to build further value through partnerships in other territories.

***Commenting on the licencing agreement, Managing Director Bill Fry said:*** "We're very excited to see this this unique, scientifically validated product being launched by Myopharm and look forward the product being available in-store across pharmacy and other distribution networks."

*Authorised for release by Bill Fry, Managing Director.*

— ENDS —

***For more information, please contact:***

#### **Company enquiries**

Bill Fry, Managing Director

Eve Investments Ltd

+61 8 6465 5500

[billf@eveinvestments.com.au](mailto:billf@eveinvestments.com.au)



P : +61 8 6465 5500

🐦 : EveInvestments

🌐 : Eve Investments Limited

W : [www.eveinvestments.com.au](http://www.eveinvestments.com.au)

### **About EVE Investments**

EVE Investments (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to help provide access to the world's best natural organic products that have demonstrated medicinal benefits and can help enrich the lives of everyday people.

For further information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter @EVEInvestments